Skip to main content
The drug industry's voice for manufacturing excellence
Production
Development
Information Technology
Compliance
Quality & Risk
Sections
Production
Development
Information Technology
Compliance
Quality & Risk
Facilities
Sectors
Special
Webinars
Podcasts
eHandbooks & White Papers
Industry News
Magazine Archives
Contact
Newsletter Subscription
Contact Us
Advertise
Follow us on
https://www.facebook.com/pages/Pharmaceutical-Manufacturing/140261116014887
http://www.linkedin.com/groups?gid=1813799
http://twitter.com/PharmaMfg
Compliance
fdasign
Regulatory Guidance
FDA issues final guidance on potency for cell and gene therapy manufacturers
The CGT manufacturing recommendations are meant to provide potency assurance considerations at every stage of development and commercialization.
Nov. 5, 2026
fda
FDA hits Xspray Pharma with Complete Response Letter for its leukemia candidate
Aug. 20, 2026
fda
FDA classifies re-inspection of Novo Nordisk’s Indiana site as Official Action Indicated
Aug. 10, 2026
cellares_cell_shuttles
Cellares sees FDA’s PreCheck pilot as catalyst for cell therapy manufacturing
July 9, 2026
fda
FDA picks seven companies for PreCheck pilot program including two CDMOs
June 30, 2026
fdawhiteoakbuilding
Novo Nordisk’s troubled Indiana site hit with Form 483 following FDA re-inspection
June 8, 2026
fdalaptopshutterstock_final
FDA PreCheck pilot draws industry support as questions on execution remain
June 2, 2026
celltherapies_shutterstock_final
Regulatory modernization for cell therapies: Bridging drug GMPs, tissue regulations, and innovation
June 2, 2026
fdawhiteoakbuilding
FDA announces one-day inspection pilot for low-risk facilities
May 7, 2026
Looking for Something?
Load More Content